Summary
Parenchymal brain tumors, which were metastases of primary lung cancer, were surgically removed from 25 patients. During the operation, patients were administered (intravenous or intracarotid) 100mg/sq m of cis-diamminedichloroplatinum (CDDP) and postoperatively, they received intravenous CDDP at 3-month intervals for 1 year. The results of this mode of treatment were compared with those obtained in 25 patients who underwent the same surgery but received other anticancer agents and in 39 patients who received no post-operative chemotherapy. Patients in the CDDP-treated group survived much longer than both of the other treatment groups. In the CDDP, but not in the other two groups, survival was significantly longer in patients who had undergone resection of their lung tumors than in those who had not. The stage of lung cancer was not found to significantly influence survival time among CDDP-treated patients. Brain metastasis was the cause of death in 12% of the patients who received CDDP, in 16% those treated with other drugs, and in 26% of those who received no chemotherapy. The incidence of local and remote intracranial tumor recurrence, including meningeal carcinomatosis, was similar in the three groups. However, the mean interval from resection of the metastatic brain tumor to local or remote recurrence was longer in the CDDP-treated group than in the other two groups, and the 2-year-survival rate was significantly higher after CDDP administration. These results suggest that CDDP may be useful in the therapy of metastatic brain tumors derived from lung cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
De Jager R, Longeval E, Klastersky J: High-dose cisplatin with fluid and mannitol-induced diuresis in advanced lung cancer: A phase II clinical trial of the EORTC lung cancer working party (Belgium). Cancer Treat Rep 64: 1341–1346, 1980
Vogl SE, Berenzweig M, Camacho F, Greenwald E, Kaplan BH: Efficacy study of intensive cis-platin therapy in advanced non-small cell bronchogenic carcinoma. Cancer 50: 24–26, 1982
Bhuchar VK, Lanzotti VJ: High-dose cisplatin for lung cancer. Cancer Treat Rep 66: 375–376, 1982
Britell JC, Eagan RT, Ingle JN, Creagan ET, Rubin J, Frytak S: Cis-dichlorodiammine (II) alone followed by adriamycin plus cyclophosphamide at progression versus cis-dichloro-diammine-platinum (II), adriamycin, and cyclophosphamide in combination for adenocarcinoma of the lung. Cancer Treat Rep 62: 1207–1210, 1978
Casper ES, Gralla RJ, Kelsen DP, Cvitkovic E, Golbey RB: Phase II study of high-dose cis-dichlorodiammineplatinum (II) in the treatment of non-small cell lung cancer. Cancer Treat Rep 63: 2107–2109, 1979
Rossof AH, Bearden JD, Cortman CA: Phase II evaluation of cis-diamminedichloroplatinum (II) in lung cancer. Cancer Treat Rep 60: 1679–1680, 1976
Kapp J, Vance R: Supraophthalmic carotid infusion for recurrent gliomas: Rationale, technique, and preliminary results for cisplatin and BCNU. J Neuro-Oncol 3: 5–11, 1985
Kolaric K, Roth A, Jelicic I, Matkovic A: Phase II clinical trial of cis-dichlorodiammine platinum (CIS DDP) in metastatic brain tumors. J Cancer Res Clin Oncol 104: 287–293, 1983
Walker RW, Allen JC: Cisplatin in the treatment of recurrent childhood primary brain tumors. J Clin Oncol 6: 62–66, 1988
Rosner D, Nemoto T, Pickren J, Lane W: Management of brain metastases from breast cancer by combination chemotherapy. J Neuro-Oncol 1: 131–7, 1983
Rosner D, Nemoto T, Lane W: Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 58: 832–9, 1986
Vick NA, Khandekar LD, Bigner DD: Chemotherapy of brain tumors: The blood-brain barrier is not a factor. Arch Neurol 34: 523–6, 1977
Wolf J: Nitrosourea as single agents in the treatment of pulmonary cancer. Cancer Treat Rep 60: 753–756, 1976
Stewart DJ, Leavens M, Maor M, Feun L, Luna M, Bonura J, Caprioli R, Loo TL, Benjamin RS: Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res 42: 2474–2479, 1982
Gormley PE, Gangji D, Wood JH, Poplack DG: Pharmaco-kinetic study of cerebrospinal fluid penetration of cis-diam-minedichloroplatinum (II). Cancer Chemother Pharmacol 5: 257–260, 1981
Ettinger DS: Ifosfamide in the treatment of non-small lung cancer. Semin Oncol 16 (suppl 3): 31–38, 1989
Lehane DE, Bryan RN, Horowitz B, DeSantos L, Ehni G, Zubler MA, Moiel R, Rudolph L, Aldama-Leubbert A, Mahoney D, Harper R: Intraarterial cis-platinum chemotherapy for patients with primary and metastatic brain tumors. Cancer Drug Delivery 1: 69–77, 1983
Feun LG, Wallace S, Stewart DJ, Chuang VP, Yung WKA, Leavens ME, Burgess MA, Savaraj N, Benjamin RS, Young SE, Tang RA, Handel S, Mavligit G, Fields WS: Intracarotid infusion of cis-diamminedichloroplatinum in the treatment of recurrent malignant brain tumors. Cancer 54: 794–799, 1984
Ginos JZ, Cooper AJL, Dhawan V, Rottenberg DA: [13N]cisplatin PET to assess pharmacokinetics of intraarterial versus intravenous chemotherapy for malignant brain tumors. J Nucl Med 28: 1844–1852, 1987
Shani J, Bertram J, Russell C, Dahalan R, Chen DCP, Parti R, Ahmadi J, Kempf RA, Kawada TK, Mugia J, Wolf W: Noninvasive monitoring of drug biodistribution and metabolism: Studies with intraarterial Pt-195m-cisplatin in humans. Cancer Res 49: 1877–1881, 1989
Stewart DJ, Benjamin RS, Zimmerman S, Caprioli RM, Wallace S, Chuang V, Calvo D III, Samuels M, Bonura J, Loo TL: Clinical pharmacology of intraarterial cis-diamminedichloroplatinum (II). Cancer Res 43: 917–920, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nakagawa, H., Fujita, T., Izumimoto, S. et al. Cis-diamminedichloroplatinum (CDDP) therapy for brain metastasis of lung cancer. J Neuro-Oncol 16, 69–76 (1993). https://doi.org/10.1007/BF01324837
Issue Date:
DOI: https://doi.org/10.1007/BF01324837